Zengpai Zheng

Dr. Zengpai Zheng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
CCChangxing Chi
Changxing Chi
ZFZhiyi Fan
Zhiyi Fan
BYBinbin Yang
Binbin Yang
HSHe Sun
He Sun
ZZZengpai Zheng
Zengpai Zheng
Background. Head and neck cancer (HNC) is the sixth most common malignancy globally, and many demographics and clinicopathological factors influence its prognosis. This study aimed to construct and validate a prognostic nomogram to predict the prognosis of HNC patients with bone metastasis (BM). Methods. A total of 326 patients with BM from HNC were collected from the SEER database as the subjects of this study. In a ratio of 7 to 3, patients were randomly divided into training and validation groups. Independent prognostic factors for HNC patients with BM were identified by univariate and multivariate Cox regression analysis. The nomogram for predicting the prognosis was constructed, and the model was evaluated by receiver operating characteristic curves, calibration curves, and decision curve analysis. Result. The independent prognostic factors for HNC patients with BM included age, primary site, lung metastasis, and chemotherapy. The area under the curve predicting overall survival at 12, 24, and 36 months was 0.768, 0.747, and 0.723 in the training group and 0.729, 0.723, and 0.669 in the validation group, respectively. The calibration curves showed good agreement between the predicted and actual values for overall survival. In addition, the decision curve analysis showed that this prognostic nomogram model has a high clinical application. Conclusion. This study developed and validated a nomogram to predict overall survival in HNC patients with BM. The prognostic nomogram has high accuracy and utility to inform survival estimation and individualized treatment decisions.

14 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QGQiusheng Guo
Qiusheng Guo
XLXianmei Lv
Xianmei Lv
ZZZengpai Zheng
Zengpai Zheng
GLGaochen Lan
Gaochen Lan
Melanoma is the most common malignant tumor, with a large patient population. Metastatic melanoma typically occurs in sites such as lymph nodes, skin, lungs, liver, brain, and bones. This metastatic spread often indicates advanced disease, with significantly decreased treatment efficacy and patient survival rates. Accurately predicting the early death (six months) rates of patients with metastatic melanoma to guide the selection of optimal treatment strategies is an urgent clinical issue in need of resolution. Patient demographic and clinical information for this study was extracted from the SEER database. Univariate and multivariate logistic regression analyses were used to screen for independent risk factors. Operating Characteristic curve (ROC) and calibration curve were used to validate the accuracy of the model. Decision curve analysis (DCA) was used to assess the model’s benefit to patients. Finally, Kaplan-Meier survival curves were plotted to show differences in patient survival across risk groups. A total of 1109 patients were included in the study and randomly allocated to a training cohort (n = 777) and a validation cohort (n = 332). Logistic regression analysis identified six variables as independent factors influencing short-term survival in patients with metastatic melanoma, which were used to construct a nomogram. The Receiver Operating Characteristic (ROC) curve demonstrated good performance of the nomogram in both the training cohort (AUC = 0.755) and the validation cohort (AUC = 0.694). The calibration curve showed good fit. Decision curve analysis (DCA) indicated that patients can derive significant benefit from using this nomogram. We have successfully developed and well validated a nomogram that accurately predicts early death (6 months) in patients with transformational melanoma. This can assist clinicians in choosing better clinical strategies for their patients.

22 December 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
YCYuyuan Chen
Yuyuan Chen
CCChangxing Chi
Changxing Chi
DCDedian Chen
Dedian Chen
SCSanjun Chen
Sanjun Chen
BYBinbin Yang
Binbin Yang
ZZZengpai Zheng
Zengpai Zheng
Background. The primary purpose of this study was to determine the risk factors affecting overall survival (OS) in patients with fibrosarcoma after surgery and to develop a prognostic nomogram in these patients. Methods. Data were collected from the Surveillance, Epidemiology, and End Results database on 439 postoperative patients with fibrosarcoma who underwent surgical resection from 2004 to 2015. Independent risk factors were identified by performing Cox regression analysis on the training set, and based on this, a prognostic nomogram was created. The accuracy of the prognostic model in terms of survival was demonstrated by the area under the curve (AUC) of the receiver operating characteristic curves. In addition, the prediction consistency and clinical value of the nomogram were validated by calibration curves and decision curve analysis. Results. All included patients were divided into a training set (n=308) and a validation set (n=131). Based on univariate and multivariate analyses, we determined that age, race, grade, and historic stage were independent risk factors for overall survival after surgery in patients with fibrosarcoma. The AUC of the receiver operating characteristic curves demonstrated the high predictive accuracy of the prognostic nomogram, while the decision curve analysis revealed the high clinical application of the model. The calibration curves showed good agreement between predicted and observed survival rates. Conclusion. We developed a new nomogram to estimate 1-year, 3-year, and 5-year OS based on the independent risk factors. The model has good discriminatory performance and calibration ability for predicting the prognosis of patients with fibrosarcoma after surgery.

26 September 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DHDaoxu Huang
Daoxu Huang
XLXuan Li
Xuan Li
YHYiling Huang
Yiling Huang
XCXiang Chen
Xiang Chen
ZZZengpai Zheng
Zengpai Zheng
Gastric signet cell carcinoma (GSRC) is a special type of gastric cancer. Due to its high metastatic rate patients usually have a poor prognosis. Accurately predicting the survival time of these patients and selecting the best treatment strategy are urgent clinical questions. All patients included in the study were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The demographic and clinical information of these patients was subjected to Cox regression analysis using SPSS software. The risk factors that were subsequently screened were used to construct and validate the nomogram through R software. A total of 1003 patients were included in this study. After Cox regression analysis, six variables (T stage, surgery status, chemotherapy, metastases status of bone, liver and lung) were identified as risk factors that independently influenced the patients’ prognosis. These variables were used to construct a nomogram, which was shown to have good predictive power by receiver operating characteristic curves and calibration curves. The AUC values for 3-, 6-, and 12-month OS prediction were 0.845, 0.793, and 0.751 in the training cohort, and 0.800, 0.735, and 0.693 in the validation cohort and decision curve analysis indicating that this nomogram could result in a good clinical benefit for the patient. We have successfully developed and validated a nomogram that accurately predicts 3-, 6- and 12-month overall survival in patients with metastatic GSRC. This can provide a theoretical basis for clinical practice and help clinicians to choose the best treatment strategy for their patients.

23 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CJChangchun Jian
Changchun Jian
DHDaoxu Huang
Daoxu Huang
YHYiling Huang
Yiling Huang
XCXiang Chen
Xiang Chen
ZZZengpai Zheng
Zengpai Zheng
Although surgical resection combined with radiotherapy is still the preferred treatment for soft tissue sarcoma, neoadjuvant chemotherapy is becoming more popular. The goal of this research is to get a large, multicenter retrospective analysis to build a practical and validated method to predict overall survival in patients. This study was a retrospective study of 902 soft tissue sarcoma patients from the Surveillance, Epidemiology, and End Results database who received neoadjuvant chemotherapy. We used the Cox multivariate model to build a nomogram for predicting overall survival and converted it into a web-based nomogram. To identify and calibrate the model, bootstrap resampling was used to draw receiver operating characteristic curves and calibration curves, as well as to test the clinical applicability of the model by plotting decision curves. A total of 634 patients were included in the training cohort, while the remaining 268 patients were included in the validation cohort. Overall survival was significantly influenced by disease stage, age, tumor size, grade, and radiation, and nomograms were created to predict overall survival. The area under the curve for predicting overall survival at 1, 3, and 5 years in the training cohort was 0.797, 0.751, and 0.739, respectively; the area under the curve for the validation cohort was 0.726, 0.747, and 0.698, respectively. The calibration curves showed that the model performs well in terms of calibration (prediction accuracy). In addition, the decision curve analysis demonstrates the good clinical application of the model, allowing for a greater net clinical benefit. For soft tissue sarcoma patients who have received neoadjuvant chemotherapy, we have developed the first novel tool to accurately predict overall survival. This tool improves clinicians’ ability to assess patient prognosis, enhances prognosis-based treatment decisions, and can be used as a guide for clinicians to consult with patients.

30 November 2023 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
JQJunqi Qiu
Junqi Qiu
XCXihan Chen
Xihan Chen
ZZZengpai Zheng
Zengpai Zheng
Cancer is one of the leading causes of death in the world. Invasive microscopic and endoscopic methods are not suitable for routine screening of gastric cancer. Therefore, the need for biomarkers that can detect quickly, efficiently, and with high sensitivity in the early stages of cancer is strongly felt. Stanniocalcin plays a role in regulating calcium and phosphorus in the body. In addition, it plays a role in neuron cell differentiation, angiogenesis, wound healing, fertility and embryo development, and cancer. This study investigated the level of expression of the Stanniocalcin 2 (STC2) gene in the serum of patients with gastric cancer. This case-control study was conducted on the samples of 60 patients with gastric cancer (cases) and 60 healthy individuals (controls). Peripheral blood samples from gastric cancer patients and volunteers as control groups were collected in tubes containing EDTA anticoagulant and were immediately subjected to serum separation. After centrifugation, serum RNA was extracted, and after cDNA synthesis, STC2 gene serum RNA level was measured by the Taq Man method and Real-time PCR using specific primers and probes. Then, the results of serum evaluations and clinicopathological information of patients and control group were collected along with the information obtained from reviewing patients' files and demographic findings, regulatory tables, and related charts. SPSS22 software was used to analyze descriptive data. According to the study results, the high expression of the STC2 gene was 31 cases in the case group and 13 cases in the control group. However, there was a significant relationship between the high expression of the STC2 gene and gastric cancer (p = 0.0001). However, there was no significant relationship between the gender of patients and high expression of the STC2 gene. However, the age of 35% of the patients was more than 65 years, and there was a significant relationship between the age of the patients and the high expression of the STC2 gene (P = 0.028). Although there was no significant relationship between the anatomical location of the cancer and the subtypes of the cancer and the high expression of the STC2 gene, there was a significant relationship between the degree of cancer differentiation and the high expression of STC2 gene (P<0.05). In general, STC2 can be used as a biomarker to determine the border and margins of the tumor. Analysis of STC2 gene expression during surgery can reduce surgical error in tumor removal and increase the success of surgery for tumor removal.